drugset / Trial / NCT01427283

A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

NCT01427283

Phase 3 Completed 450 enrolled Purdue Pharma LP
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective is to assess the efficacy of oxycodone/naloxone controlled-release tablets (OXN) for the management of opioid-induced constipation (OIC) compared with oxycodone controlled-release tablets (OXY) in subjects with moderate to severe low back pain and opioid-induced constipation who require around-the-clock opioid therapy.

Timeline

Start
2011-08
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Oxycodone Other / unclassified 10 mg Oral
Comparator Oxycodone Other / unclassified 40 mg Oral
Subject Oxycodone/Naloxone Unknown 10 mg Oral
Subject Oxycodone/Naloxone Unknown 40 mg Oral

Indications

No indication recorded.